• Pharmacology
  • Allergy, Immunology, and ENT
  • Cardiology
  • Emergency Medicine
  • Endocrinology
  • Adolescent Medicine
  • Gastroenterology
  • Infectious Diseases
  • Neurology
  • OB/GYN
  • Practice Improvement
  • Gynecology
  • Respiratory
  • Dermatology
  • Mental, Behavioral and Development Health
  • Oncology
  • Rheumatology
  • Sexual Health
  • Pain

ADHD drug gets three more dosage strengths

Article

Shire's ADHD treatment lisdexamfetamine (Vyvanse) was approved by the FDA in three new dosage strengths. The current 30 mg-, 50 mg and 70 mg-dosage strengths will be joined by 20 mg-, 40 mg-, and 60 mg-dosage strengths. They will be available in the second quarter of this year.

Lisdexamfetamine is approved to treat ADHD in children between 6 and 12 years of age. Many who receive treatment have their dose levels titrated up or down. These additional dosage strengths could offer a more gradual process in titrating, 10 mg at a time.

Related Videos
Donna Hallas, PhD, CPNP, PPCNP-BC, PMHS, FAANP, FAAN
Image credit: Kyle Dykes
J. Thomas Megerian, MD, PhD, FAAP | Author provided
Colleen Kraft, MD | Image Credit: Children's Hospital Los Angeles
Image Credit: Contemporary Pediatrics®
Related Content
Does acetaminophen intake during pregnancy influence children’s risk of neurodevelopmental disorders? | Image Credit: © Alik Mulikov - © Alik Mulikov - stock.adobe.com.

Does acetaminophen intake during pregnancy influence children’s risk of neurodevelopmental disorders?

April 9th 2024
Article

A recently published study in JAMA sought to determine if there is a link between acetaminophen use during pregnancy and children’s risk of developing autism, ADHD, or intellectual disabilities.

ADHD Medications: A Look at Their Safety Profile

ADHD Medications: A Look at Their Safety Profile

October 17th 2012
Podcast

Each year in this country, physicians prescribe medications to treat ADHD in nearly 3 million children. The safety of these agents has been the subject of some debate.

DSMB recommends continuation of phase 3 trial evaluating central precocious puberty treatment | Image Credit: © Dzmitry - © Dzmitry - stock.adobe.com.

DSMB recommends continuation of phase 3 trial evaluating central precocious puberty treatment

April 3rd 2024
Article

The single-arm study has an estimated enrollment of 93 participants, made up of females aged 2 to 8 years and males aged 2 to 9 years with CPP.

Exploring kindergarten readiness in children born preterm | Image Credit: © dusanpetkovic1 - © dusanpetkovic1 - stock.adobe.com.

Exploring kindergarten readiness in children born preterm

March 20th 2024
Article

Many preterm infants are considered to be “caught up” to their peers during the toddler years, but evidence is mounting that even late preterm infants may experience ongoing academic and developmental delays.

Black youths and females face higher risk for foster care involvement | Image Credit: © Vitalii Vodolazskyi - © Vitalii Vodolazskyi - stock.adobe.com.

Black youths and females face higher risk for foster care involvement

February 14th 2024
Article

Results demonstrated that foster care involvement does vary based on age and sex, with Black youths and females disproportionately effected.

Maternal tobacco use tied to late childhood neurocognition deficits | Image Credit: © highwaystarz - © highwaystarz - stock.adobe.com.

Maternal tobacco use tied to late childhood neurocognition deficits

February 13th 2024
Article

Compared to children with no maternal tobacco usage during pregnancy, those exposed had associations to childhood neurocognition deficits.

© 2024 MJH Life Sciences

All rights reserved.